G(M1) Ganglioside clinical trials
Its developmentBy Qilu Pharmaceutical, step by step2 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.How each study uses G(M1) Ganglioside is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the G(M1) Ganglioside studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- GM1
- 6
Studies by the year they started
7 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 1999 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2021 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 5
Qilu Pharmaceutical Co., Ltd. (2) · General Hospital of Shenyang Military Region (1) · Sun Yat-sen University (1) · Yuhong Li (1) · Thomas Jefferson University (1) · Peking University Cancer Hospital & Institute (1)
Studies
Open first, then newest update. How each study uses G(M1) Ganglioside is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Study to Evaluate the Efficacy and Safety of Monosialotetrahexosylganglioside Sodium Injection in Parkinson's Disease Participants With Motor FluctuationsNot yet recruitingPhase 2Qilu Pharmaceutical Co., Ltd.NCT07585565Written as GM1How we know
- GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast CancerRecruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT06994507Written as GM1How we know
- An Exploratory Study of Ganglioside GM1 in Acute Ischemic StrokeCompletedPhase 4General Hospital of Shenyang Military RegionNCT04952064Written as Monosialoganglioside GM1How we know
- Effect of GM1 in Prevention of Taxanes Induced Neurotoxicity in Operable Breast CancerCompletedPhase 3Sun Yat-sen UniversityNCT02468739Written as Ganglioside-monosialic acidHow we know
- Effect of GM1 in Prevention of Oxaliplatin Induced Neurotoxicity in Stage II/III Colorectal CancerCompletedPhase 3Yuhong LiNCT02251977Written as GM1How we know
- Monosialoganglioside Preventing Neurotoxicity Induced by Albumin-bound Paclitaxel Chemotherapy in Lung Cancer PatientsStatus unknownPhase 2Peking University Cancer Hospital & InstituteNCT02500810Written as monosialogangliosideHow we know
- GM1 Ganglioside Effects on Parkinson's DiseaseCompletedPhase 2Thomas Jefferson UniversityNCT00037830Written as GM1 gangliosideHow we know